Jacob Plieth — Cross-trial mPFS comparison for $BDTX is $AVBP, which clailmed 16.0 months in 1st-line PACCm patients at #WCLC25.↗
December 2025 · 3 mentions
Dec 5
Jacob Plieth — Now $ORIC goes after $AVBP & $BDTX in 1st-line PACC lung cancer, and shows why it abandoned relapsed HER2 ex20. Via @ApexOnco -> https://t.co/valRcL0Fvd https://t.co/AITjRMe…↗
Dec 3
Jacob Plieth — $BDTX currently off 17% (earlier -30%) on yet another strategic pivot. @ApexOnco take on today's silevertinib data https://t.co/gaR3OPzVPM $AVBP↗
Dec 3
Jacob Plieth — @LionsWatson I'm so sorry for being insufficiently enthusiastic with my praise for $BDTX. Anyway, here's $AVBP https://t.co/ldDzAdxPGc↗
October 2025 · 2 mentions
Oct 22
Jacob Plieth — Who won #ESMO25 and who lost? Via @ApexOnco
https://t.co/EWzHIIH1Ck
$IOBT $CELC $RCUS $CGEM $IDYA $NUVL $AGEN $GILD $DSNKY $INCY $CATX $LPTX $OLMA $SMMT $AVBP $GMAB $EXEL $CGEN $Z…↗
Oct 20
Jacob Plieth — Good morning biotwitter! If you're catching up with #ESMO25 here's what we've published over the weekend https://t.co/lzhy6k4Raz
Stocks to watch this morning: $GMAB $CELC $IOBT $MR…↗
July 2025 · 2 mentions
Jul 25
Jacob Plieth — If I understand correctly LaNova's (Sino's) anti-CDH17 LM-350 just got IND approved to start US trials https://t.co/9IqnIu6PyY $AVBP $GSK↗
Jul 21
Jacob Plieth — $AVBP Furvent PFS data for firmonertinib in 1L EGFR exon 20ins NSCLC slips from 2025 to "early 2026". Relevant for Dizal Zegfrovy, I guess.↗
June 2025 · 1 mention
Jun 20
Jacob Plieth — $AVBP
Background: https://t.co/LHVE3PxItj↗